Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial): Final results.
E. Mitry
Consultant or Advisory Role - Roche
Honoraria - Pfizer; Roche
O. Bouche
Consultant or Advisory Role - Pfizer (U)
J. Seitz
No relevant relationships to disclose
P. Etienne
No relevant relationships to disclose
J. Legoux
Honoraria - Roche
Other Remuneration - Pfizer
T. Aparicio
No relevant relationships to disclose
G. Breysacher
No relevant relationships to disclose
C. Lecaille
No relevant relationships to disclose
T. Lecomte
No relevant relationships to disclose
J. Jouve
No relevant relationships to disclose